Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy.

Eli Lilly LLY secured a significant milestone on Friday when it became the first company in the healthcare space to reach $1 trillion in market value. With this breakthrough, Lilly is now the second ...

Drug giant Eli Lilly is launching an AI-powered drug discovery platform. While it won't generate any revenue, this initiative could pay off in the long run. Still, there are plenty of other reasons to ...

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also ...